Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Intercept Pharmaceuticals ( ICPT) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Intercept Pharmaceuticals as such a stock due to the following factors:

  • ICPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $358.0 million.
  • ICPT is up 2.1% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ICPT with the Ticky from Trade-Ideas. See the FREE profile for ICPT NOW at Trade-Ideas

More details on ICPT:

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. ICPT has a PE ratio of 52.6. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

The average volume for Intercept Pharmaceuticals has been 539,900 shares per day over the past 30 days. Intercept has a market cap of $6.0 billion and is part of the health care sector and drugs industry. The stock has a beta of -3.22 and a short float of 9.9% with 0.67 days to cover. Shares are up 320.5% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone